Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02614560 · ClinicalTrials.gov registry record · Phase 1
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
A Phase 1 study, sponsored by Seagen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02614560 is a Phase 1 study that was terminated before completion, run by Seagen. The registered enrollment target is 14 participants.
The verdict
NCT02614560, a Phase 1 study, was terminated before completion, sponsored by Seagen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This study will examine the safety and anti-leukemic profile of SGN-CD33A (vadastuximab talirine) in patients with relapsed chemo-resistant AML, who are given vadastuximab talirine in sequence with standard treatments before a planned stem cell transplant, or as maintenance therapy after a stem cell transplant. The main purpose of the study is to find the best dose and determine the anti-leukemic activity of vadastuximab talirine, given either pre- or post-allogeneic stem cell transplant (alloSCT) for adults with relapsed or refractory AML. This will be determined by assessing the safety and tolerability of vadastuximab talirine. In addition, the pharmacokinetic profile and anti-leukemic activity of the study treatment will be assessed.
Interventions
- DRUG Fludarabine
- DRUG Melphalan
- DRUG vadastuximab talirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-09-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02614560
The ClinicalTrials.gov registry entry for NCT02614560 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fludarabine is the first listed.
NCT02614560 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02614560 about?
NCT02614560 is a clinical study titled "A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients". This study will examine the safety and anti-leukemic profile of SGN-CD33A (vadastuximab talirine) in patients with relapsed chemo-resistant AML, who are given vadastuximab talirine in sequence with standard treatments before a planned stem cell transplant, or as maintenance therapy after a stem cell...
What is the current status of trial NCT02614560?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2015-11. Estimated completion is 2017-09-14.
What interventions are being tested in trial NCT02614560?
The interventions under investigation include: Fludarabine (DRUG), Melphalan (DRUG), vadastuximab talirine (DRUG).
Who is sponsoring clinical trial NCT02614560?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.